Table 3 Characteristics of patients with enteropathic chronic recurrent multifocal osteomyelitis
No. | Gender | No. foci | Autoantibodies | Histology | Disease course | Delay (years) | Therapy | Outcome | HLA-B27 | FCP (μg/g) | Family history |
|---|---|---|---|---|---|---|---|---|---|---|---|
1. | F | 7 | ASCA positive | NS colitis | 1. CRMO, arthritis 2. colitis + CRMO relapse | 5.0 | SSZ -- > P-- > ADA + MTX -- > none | remission, now without therapy | negative | 1000 | II. HLA-B27 AS |
2. | M | 10 | p-ANCA positive | CD | 1. IBD 2. PPP 3. CRMO + IBD relapse | 4.0 | AZA, IFX, IFX + MTX -- > ADA | relapsing IBD and CRMO | negative | 1736 | I. IBD |
3. | F | 2 | ASCA positive | CD | 1. CRMO, arthritis 2. IBD 3. HSP 4. acute uveitis | 0.5 | SSZ -- > ETA + MTX -- > ADA, AZA | remission on therapy | positive | 350 | I. IBD |
4. | F | 9 | ASCA positive | CD | 1. IBD 2. CRMO + PPP | 4.0 | AZA -- > IFX-- > ADA-- > ADA + SSZ-- > ADA + MTX + SSZ | remission on therapy | negative | 3329 | II. psoriasis |
5. | F | 3 | p-ANCA positive | UC | 1. IBD 2. IBD relaps + CRMO | 2.5 | P + AZA-- > 5-ASA-- > ADA + MTX | remission on therapy | negative | 938 | negative |
6. | F | 11 | negative | UC, PSC | 1. IBD, PSC 2. CRMO | 4.0 | 5-ASA, UDCA, PAM-- > ADA | active CRMO, IBD in remission | negative | 1680 | II. IBD |
7. | M | 7 | p-ANCA positive | CD | 1. CRMO, arthritis 2. IBD (arthritis and CRMO in remission) | 7.5 | NSAID-- > SSZ, P, MTX -- > ADA | active IBD, CRMO in remission | negative | 1230 | unknown |
8. | M | 9 | negative | CD | 1. CRMO 2. IBD (CRMO in remission) | 4.0 | NSAID-- > P-- > 5-ASA-- > non-compliance | active IBD, CRMO in remission | negative | 545 | I. IBD, II. psoriasis |